S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:XNCR

Xencor Stock Forecast, Price & News

$34.97
-0.12 (-0.34%)
(As of 01/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$34.82
$36.69
50-Day Range
$33.74
$41.63
52-Week Range
$30.12
$58.35
Volume
199,624 shs
Average Volume
205,802 shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.76
30 days | 90 days | 365 days | Advanced Chart
Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.


Xencor logo

About Xencor

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
202
Year Founded
N/A

Sales & Book Value

Annual Sales
$122.69 million
Book Value
$9.96 per share

Profitability

Net Income
$-69.33 million
Pretax Margin
-2.53%

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,330,000
Market Cap
$2.05 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/20/2022
Next Earnings (Estimated)
2/22/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

414th out of 1,415 stocks

Pharmaceutical Preparations Industry

191st out of 682 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor
or view top-rated stocks.

How has Xencor's stock price been impacted by COVID-19 (Coronavirus)?

Xencor's stock was trading at $28.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XNCR shares have increased by 24.4% and is now trading at $34.97.
View which stocks have been most impacted by COVID-19
.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Xencor
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.06. The biopharmaceutical company had revenue of $19.68 million for the quarter, compared to analyst estimates of $17.63 million. Xencor had a negative net margin of 2.53% and a negative trailing twelve-month return on equity of 0.68%. During the same quarter in the prior year, the business posted ($0.22) EPS.
View Xencor's earnings history
.

What price target have analysts set for XNCR?

9 equities research analysts have issued 12 month target prices for Xencor's shares. Their forecasts range from $34.00 to $71.00. On average, they anticipate Xencor's share price to reach $54.13 in the next year. This suggests a possible upside of 54.8% from the stock's current price.
View analysts' price targets for Xencor
or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Bassil I. Dahiyat, President, Chief Executive Officer & Director
  • John J. Kuch, Chief Financial Officer & Senior Vice President
  • John R. Desjarlais, Chief Scientific Officer & Senior VP-Research
  • Allen Yang, Chief Medical Officer & Senior Vice President
  • Celia Eckert, Secretary, General Counsel & Vice President

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Xencor stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor
.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., and State of Alaska Department of Revenue. Company insiders that have sold Xencor company stock in the last year include Allen Yang, Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor
or view top insider-selling stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $34.97.

How much money does Xencor make?

Xencor has a market capitalization of $2.05 billion and generates $122.69 million in revenue each year. The biopharmaceutical company earns $-69.33 million in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 202 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

Where are Xencor's headquarters?

Xencor is headquartered at 111 WEST LEMON AVENUE, MONROVIA CA, 91016.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.